盘前要闻 1、更大力度提振消费！央行等三部门最新部署，专家解读来了 类型：行业 情绪影响：正面 3、多部门部署明年经济工作：将根据形势变化出台实施增量政策 类型：宏观 情绪影响：正面 中央经济工作会议为2026年经济工作指明施政方向后，央行、财政部等多部门密集发声，根据会议部署 细化落实措施。央行表示，要把促进经济稳定增长、物价合理回升作为货币政策的重要考量。中央财办 副主任韩文秀表示，2026年将根据形势变化出台实施增量政策，要协同发挥存量政策和增量政策集成效 应。 12月14日，央行等三部门联合发布《关于加强商务和金融协同更大力度提振消费的通知》。其中指出加 大消费重点领域金融支持，开展多层次、多渠道、多样化的促消费活动和信息共享。专家表示，《通 知》提升入境支付便利性、支持"首发经济"等内容，在政策合力与市场创新协同作用下，深度释放内需 潜能。 2、茅台推出控量政策，飞天茅台批价回涨，零售均价超1800元 类型：公司 情绪影响：正面 12日晚间，有消息人士称，贵州茅台近期将推出一个涵盖短期和中长期的控量政策。短期方面，贵州茅 台在12月内停止向经销商发放所有茅台产品；中长期方面，明年贵州茅台计划削减非标 ...

Investment Rating - The report maintains a "Recommendation" rating for Jiuan Medical (002432) with a target price of 53 CNY, while the current price is 41.63 CNY [4][8]. Core Insights - The company's revenue for the first three quarters of 2025 was 1.069 billion CNY, a decrease of 48.89% year-on-year, while the net profit attributable to the parent company was 1.589 billion CNY, an increase of 16.11% [2][8]. - The decline in revenue is primarily attributed to a significant drop in government orders for reagent kits, which decreased by 860 million CNY compared to the same period last year [8]. - The C-end reagent kit business showed a quarter-on-quarter revenue increase in Q3 2025, reaching 304 million CNY, up 17.8% from Q2, driven by sales growth in the iHealth product series and internet medical services [8]. - The asset management business contributed significantly to profits, with net profit for the first three quarters of 2025 reaching 1.589 billion CNY, exceeding the revenue of 1.069 billion CNY, mainly from investment income and fair value changes totaling 1.814 billion CNY [8]. - The company is actively promoting the development of new products, including Continuous Glucose Monitoring (CGM), a four-in-one test kit, and AI smart hearing aids, with the latter expected to enhance patient convenience and reduce costs [8]. Financial Summary - For 2025, the projected net profit attributable to the parent company is 2.341 billion CNY, with a year-on-year growth of 40.3%, and the earnings per share (EPS) is expected to be 5.04 CNY [4][8]. - The company's total revenue is forecasted to decline to 1.411 billion CNY in 2025, with a year-on-year decrease of 45.6%, before recovering to 1.610 billion CNY in 2026 [4][8]. - The price-to-earnings (P/E) ratio is projected to be 8 for 2025 and 7 for 2027, indicating a favorable valuation compared to historical levels [4][8].

Group 1: Business Strategy and Investment - The company has established a dual business model focusing on medical health operations and large asset allocation investments, aiming for stable profits and cash flow [2][3] - The asset allocation strategy is inspired by Yale University's endowment model, targeting a long-term return of 6%-10% per year [3] - As of mid-2025, the company's private equity assets accounted for 12.6% of its total assets, with significant investments in hard technology and healthcare sectors [3][4] Group 2: Product Development and Market Expansion - The company plans to launch a four-in-one respiratory test product, currently in clinical trials, to address seasonal respiratory diseases [5] - The three-in-one test product has achieved stable sales in the consumer market, with a focus on expanding sales channels [8] - The company is actively developing AIoT diabetes management tools, aiming to enhance chronic disease management through technology [12][23] Group 3: Financial Performance and Shareholder Value - The company has conducted five share buyback programs since 2021, totaling approximately ¥2.88 billion, with a sixth program currently underway [7][20] - As of Q3 2025, the company reported a revenue of ¥3.04 billion, a 17.8% increase from the previous quarter, driven by iHealth products and internet medical services [24][25] - The company has committed to distributing at least 30% of its cumulative net profit as dividends over the next three years [20][21] Group 4: Market Challenges and Future Outlook - The company faces challenges in the U.S. market due to tariff issues, but has established overseas production capabilities to mitigate these impacts [29] - The diabetes care service model has expanded to approximately 50 cities and 424 hospitals, managing over 366,000 patients in China [10][22] - The company anticipates significant growth in the diabetes care market, with a target of managing 1 million patients within three years [22]